MBIO vs. CANF, EDSA, GLTO, UNCY, TLPH, BCTX, FLGC, KTRA, UPC, and AVTX
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Can-Fite BioPharma (CANF), Edesa Biotech (EDSA), Galecto (GLTO), Unicycive Therapeutics (UNCY), Talphera (TLPH), BriaCell Therapeutics (BCTX), Flora Growth (FLGC), Kintara Therapeutics (KTRA), Universe Pharmaceuticals (UPC), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
Mustang Bio (NASDAQ:MBIO) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Mustang Bio received 166 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 5.66% of users gave Can-Fite BioPharma an outperform vote.
Mustang Bio has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 2.1% of Mustang Bio shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Mustang Bio has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,027.46%. Can-Fite BioPharma's return on equity of -113.75% beat Mustang Bio's return on equity.
Can-Fite BioPharma has higher revenue and earnings than Mustang Bio. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Mustang Bio currently has a consensus price target of $12.00, indicating a potential upside of 3,227.79%. Can-Fite BioPharma has a consensus price target of $18.00, indicating a potential upside of 385.18%. Given Mustang Bio's higher probable upside, research analysts clearly believe Mustang Bio is more favorable than Can-Fite BioPharma.
In the previous week, Mustang Bio had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for Can-Fite BioPharma. Mustang Bio's average media sentiment score of 1.44 beat Can-Fite BioPharma's score of 0.88 indicating that Mustang Bio is being referred to more favorably in the media.
Summary
Mustang Bio beats Can-Fite BioPharma on 10 of the 18 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
Free MBIO Stock Alerts